These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35248476)

  • 1. Convalescent plasma to deliver therapeutic antibodies against COVID-19.
    Senefeld JW; Casadevall A; Joyner MJ
    Trends Mol Med; 2022 May; 28(5):435-436. PubMed ID: 35248476
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients.
    Gharbharan A; GeurtsvanKessel CH; Jordans CCE; Blaauw M; van der Klift M; Hassing RJ; Smits-Zwinkels M; Meertens M; van den Hout EC; de Man AM; Hageman I; Bogers S; van der Schoot CE; Swaneveld F; Anas AA; Rokx C; Rijnders BJA
    Clin Infect Dis; 2022 Apr; 74(7):1271-1274. PubMed ID: 34293119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thinking more about therapy with convalescent plasma for COVID-19 patients.
    Han G; Zhou YH
    Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations.
    Franchini M; Mengoli C; Ballotari A; Glingani C
    Transfus Clin Biol; 2022 May; 29(2):186-187. PubMed ID: 34690072
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma.
    Nguyen D; Xiao J; Simmonds P; Lamikanra A; Odon V; Ratcliff J; Townsend A; Roberts DJ; Harvala H
    J Infect Dis; 2022 Mar; 225(6):971-976. PubMed ID: 34751775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model.
    Haagmans BL; Noack D; Okba NMA; Li W; Wang C; Bestebroer T; de Vries R; Herfst S; de Meulder D; Verveer E; van Run P; Lamers MM; Rijnders B; Rokx C; van Kuppeveld F; Grosveld F; Drabek D; Geurts van Kessel C; Koopmans M; Bosch BJ; Kuiken T; Rockx B
    J Infect Dis; 2021 Jun; 223(12):2020-2028. PubMed ID: 34043806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response).
    De Santis GC; Calado RT
    Emerg Infect Dis; 2022 May; 28(5):1083-1084. PubMed ID: 35447061
    [No Abstract]   [Full Text] [Related]  

  • 8. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants.
    Bellusci L; Golding H; Khurana S
    J Clin Invest; 2023 Apr; 133(8):. PubMed ID: 36821375
    [No Abstract]   [Full Text] [Related]  

  • 10. Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2.
    Müller K; Girl P; Giebl A; von Buttlar H; Dobler G; Bugert JJ; Gruetzner S; Wölfel R
    J Clin Virol; 2021 Sep; 142():104912. PubMed ID: 34298379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
    Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
    Viruses; 2021 May; 13(5):. PubMed ID: 34065987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
    Uriu K; Kimura I; Shirakawa K; Takaori-Kondo A; Nakada TA; Kaneda A; Nakagawa S; Sato K;
    N Engl J Med; 2021 Dec; 385(25):2397-2399. PubMed ID: 34731554
    [No Abstract]   [Full Text] [Related]  

  • 13. On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy.
    Focosi D; Franchini M; Casadevall A
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
    Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
    Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Dose Convalescent Plasma for Treatment of Severe COVID-19.
    Focosi D; Casadevall A
    Emerg Infect Dis; 2022 May; 28(5):1083. PubMed ID: 35450567
    [No Abstract]   [Full Text] [Related]  

  • 16. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.
    Betrains A; Godinas L; Woei-A-Jin FJSH; Rosseels W; Van Herck Y; Lorent N; Dierickx D; Compernolle V; Meyfroidt G; Vanderbeke L; Vergote V; Lagrou K; Verhamme P; Wauters J; Vermeersch P; Devos T; Maes P; Vanderschueren S
    Br J Haematol; 2021 Mar; 192(6):1100-1105. PubMed ID: 33314018
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing activity to SARS-CoV-2 in 1.2 to 10.0 month convalescent plasma samples of COVID-19: A transversal surrogate in vitro study performed in Quito-Ecuador.
    Villacrés-Granda B; Paz E; Burbano MJ; Villacrés-Granda I; Armijos D; Aguirre M
    J Med Virol; 2022 Sep; 94(9):4246-4252. PubMed ID: 35585654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and application of therapeutic antibodies against COVID-19.
    Ning L; Abagna HB; Jiang Q; Liu S; Huang J
    Int J Biol Sci; 2021; 17(6):1486-1496. PubMed ID: 33907512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.